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1 Introduction
The health care system in China has been undergoing
reforms for the past three decades. New policies and reg-
ulations are being developed to better meet the health
needs of over a billion people. As reform programs expand,
the need for scientific evidence increases, to enable accu-
rate evaluation of the impact of new policies. In this con-
text, health economics and outcomes research (HEOR) will
be instrumental to evidence-based decision making and is
expected to play a major role in China’s health care reform.
2 Reform of China’s Health Care System
The goal of China’s health care reform is to establish a
system that provides safe, effective, convenient, and
affordable services to meet the basic health care needs of
the 1.3 billion people living in the country’s rural and
urban areas [1]. To reach this goal, much effort has been
devoted to setting up a health care infrastructure (provider
side) and a public health insurance system (payer side).
As of 2011, there were 954,389 medical institutions and
more than 2.5 million licensed physicians in China, sub-
stantial increases over 1978 numbers (170,000 medical
institutions and 1.0 million licensed physicians) [2]. The
current multi-level health insurance system includes Urban
Employee Basic Medical Insurance (UEBMI), covering
employed urban residents; Urban Resident Basic Medical
Insurance (URBMI), for unemployed urban residents; and
the New Rural Cooperative Medical System (NRCMS), for
people in rural areas. As of 2011, these three national
insurance plans were providing coverage for 95 % of the
population in China [3]. NRCMS is the largest health plan,
covering 832 million people—97 % of the rural population
[4]. In addition, commercial health insurance plans can be
purchased to supplement the national health plans.
Improvements in the health care infrastructure and
health insurance coverage have in turn led to better health
outcomes in the Chinese population. For example, the
average life expectancy has increased from 67.9 in 1981 to
73 in 2005, and the infant mortality rate has declined from
50.2 per 1,000 live births in 1991 to 12.1 per 1,000 live
births in 2011 [2].
3 Current Challenges and Future Directions
Despite such achievements over the past 30 years, China’s
current health care system still faces a number of chal-
lenges. Among these are regional disparities in resource
allocation and health insurance coverage, inadequate gov-
ernment funding of public hospitals, and an inefficient and
inadequately monitored pharmaceutical market.
Regional disparities, particularly between urban and
rural geographies, are evident on both provider and payer
sides, reflecting the imbalance in health care system
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developments between the two regions. In terms of health
care resource allocation, the majority of medium-to-large
hospitals are still located in urban areas. Access to high-
quality health care services remains a challenge for rural
residents, which account for about half of the total popu-
lation [2]. Insufficient insurance coverage further impacts
access in rural areas, as high out-of-pocket costs for serious
and chronic diseases often take a considerable financial toll
on rural families.
In both rural and urban areas, public hospitals, which
provide 91% of outpatient and inpatient services in China
[2], are caught in a financial squeeze. Government spend-
ing on health care has been relatively low for many years,
with direct government subsidies accounting for only 9 %
of public hospital revenues in 2011 [2]. In addition, the
government sets prices for many medical services far
below actual costs, to improve affordability of these ser-
vices; as a result, hospitals have to shoulder the financial
loss from providing medical services. To make up for lost
revenue, most hospitals rely on prescription drug sales and
sophisticated diagnostic procedures, which has led to over-
prescription of expensive and unnecessary drugs and tests
[5]. This not only wastes health care resources, it also
imposes a heavy financial burden on patients and payers.
Another issue facing China’s health care system is the
inefficiency of the pharmaceutical supply chain. Manu-
facturers have little incentive to produce low-cost, effective
drugs due to small profit margins. Drug costs are inflated as
a result of the multiple layers of distribution between
manufacturers and hospitals. In addition, and of significant
concern, drug safety and adverse events remain inade-
quately monitored and managed, presenting potential
public health problems.
The Chinese government has proposed and implemented
a series of new reform measures to address these chal-
lenges. Efforts to increase public health funds and ensure
continuous investment in basic health care infrastructure
are likely to help further reduce urban-rural disparities in
resource allocation. NRCMS coverage is also being
expanded and the benefits of national health insurance
plans increased, enabling access to a wider range of health
care services, particularly among rural residents [6]. In
2012, the Ministry of Health expanded the national
essential drug list (EDL), adding 213 more drugs than those
on the 2009 formulary [7]. Drugs on the EDL are available
through primary care centers with no mark-up in pricing,
therefore expanding the list may further enhance the
accessibility and affordability of a broader range of treat-
ments and help narrow the gap in medical services pro-
vided to urban and rural areas. In addition, the government
is taking steps to limit the financial incentives for hospitals
to sell expensive and unnecessary drugs and diagnostic
tests by, for example, capping the percentage of total
hospital revenues derived from drug sales and experi-
menting various bundled payment schemes such as capi-
tation payment, single-disease payment and per diem
payment [8]. These bundled payments would only reim-
burse hospitals a fixed amount at patient, disease, or per
diem level, thus reducing incentives to prescribe costly
medicines or procedures.
4 Role of Health Economics and Outcomes Research
to China’s Health Care Reforms
HEOR has long played an essential role in health policy
and health care decision making in many countries [9–13].
In China, with reform measures in place, public health
officials have begun to recognize the need to generate
scientific evidence on the effects of new policies to further
inform their decision making. Health economics has thus
attracted more attention in recent years; during the past
decade, a growing body of health economics and outcome
research literature has emerged from China, e.g. studies
assessing disease burden, evaluating health care policies,
and comparing interventions in China [14–21]. In addition,
to improve research quality and standardize methods,
multiple academic groups in China are proactively devel-
oping guidelines for health economics research. One such
guideline, published in 2011, details the methods and best
practices in pharmacoeconomic evaluations [22]. Con-
ceivably, the availability of more HEOR would lead to
better policymaking and play a critical role in continuing
the advancement of reform efforts.
However, the growth and impact of HEOR is limited by
lack of high-quality, reliable data sources. Payers and
providers both realize the importance of considering the
economic values of alternative treatments when making
formulary decisions; however, to date the majority of
pharmacoeconomic evaluations are cost-minimization
studies that include only drug costs. Lack of evidence of
comparative effectiveness and medical cost offsets prevent
the appropriate implementation of cost-effectiveness ana-
lysis. High-quality longitudinal databases integrating
inpatient, outpatient, and pharmacy resource utilization,
and including clinical outcomes, are in high demand but
have yet to be developed.
On a more positive note, substantial efforts have been
devoted to developing and collecting data useful in HEOR.
With the development of health informatics systems, many
hospitals in China have switched from paper medical charts
to electronic medical records (EMR). Recently, large, high-
quality, electronically-linked databases for research use
have started to emerge [23, 24]. These databases feature
comprehensive clinical and economic information and
large sample sizes, even for rare diseases. Also, with the
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expansion of national health insurance coverage, national
and regional insurance claims databases are being con-
structed and upgraded [25, 26]. In addition, other national
and regional data sources (e.g. surveys) have become
increasingly available to researchers [27, 28]. Development
of a standard, accurate coding system is an ongoing effort
and will improve the utility of these data sources, partic-
ularly large EMR and claims databases, in future HEOR
efforts.
5 In this Special Issue
This special issue of PharmacoEconomics brings together
studies addressing aspects of China’s current health care
system from an HEOR perspective. Several of the studies
also highlight areas of particular challenge in the state’s
health care reform initiatives. One study assesses the extent
to which the Essential Medicines Program has promoted
rational use of medicine and removed the incentives for
primary care institutions to prescribe expensive drugs [29].
The study uses China’s National Health Services Survey
data and shows that removal of economic incentives alone
may not be enough to change the health care providers’
behaviors and improve rational use of medicines. However,
as the authors suggest, the data period may not be long
enough to allow the Essential Medicines Program to take
effect. More accurate measures defining ‘rational use’ and
future studies are needed to further address this important
question. Another study uses a simultaneous equation
modeling approach and finds a positive effect of the
URBMI on inpatient health service utilization [28]. It would
be interesting to further investigate whether the increase in
health services utilization enables patients who could not
afford health care to receive appropriate care, or reflects
overuse of health care services. Additionally, an empirical
study describes pharmaceutical pricing under the interplay
of market competition and government control in Chinese
hospitals [30]. The study provides a helpful introduction to
familiarize readers with the systems of pharmaceutical
products’ pricing and procurement in China; the findings
suggest that the local leading manufacturers may be in a
disadvantageous position as a result of market competition
and government regulations [30]. Lastly, a 20-year study
provides an overview of the trends and factors determining
pharmaceutical expenditure [31]. It presents empirical
evidence on the increasing trend in pharmaceutical expen-
diture in China. Although economic growth may check the
increase in the ratio between total pharmaceutical expen-
diture and total health care expenditure, the high ratio
indicates that measures need to be taken to further reduce
the pharmaceutical expenditure in China [31].
The issue also includes several disease-specific topics.
An analysis of treatment for venous thromboembolism
based on Chinese EMRs data revealed potential under-
treatment, suboptimal outcomes, and substantial economic
burden among hospitalized patients with the disease [23].
A study among patients with acute myocardial infarction in
Shanghai found the inclusion of heart stents in the insur-
ance benefit did not achieve intended improvement of
equality on health care utilization without properly
addressing health care providers’ incentives [32]. A cost-
utility analysis showed that the adjuvant therapy with
capecitabine and oxaliplatin recommended by the Chinese
National Comprehensive Cancer Network guidelines was
cost-effective for the treatment of resectable gastric cancer
patients in the long run but not in the short term, suggesting
the importance of considering the long-term economic
value of new technology in China’s health care system
[33].
All of these studies provide interesting findings with
implications for policy and medical decision making. As
China expands its efforts to reform the national health care
system, the need for rigorous, relevant HEOR will grow.
The editors of this special issue hope that evidence from
these studies will be informative to public health policy
makers and help to optimize the allocation and utilization
of health care resources in China.
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